AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
- ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2
- ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease on track for interim data in H2
- ACI-24.060 for Alzheimer’s disease (AD) received FDA Fast Track designation
- ACI-35.030 ReTain Phase 2b program in preclinical (pre-symptomatic) AD patients, initiated by collaboration partner
- Cash of CHF 103 million at year end, plus the CHF 15 million milestone payment received on February 1, 2024 and the next CHF 25 million ACI-35.030-related milestone, provides funding into 2026
AC Immune SA, a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the year ended December 31, 2023, and provided a corporate update.